Psyence Biomedical Ltd. Archives

Why Psyence Biomedical Ltd.’s Australian trial strategy could shape global psychedelic drug development pathways

Psyence Biomedical Ltd. advances NPX-5 dosing in Australia. Discover how this trial strategy could shape global psychedelic drug development.

Pharma & Biotech

Psyence Biomedical Ltd. advances natural psilocybin development with Phase IIb cancer distress trial

by Soujanya Ravi
March 3, 2026
0 Comments

Psyence Biomedical Ltd. advances natural psilocybin therapy in a Phase IIb cancer distress trial. Explore what this means for psychedelic medicine development.